At 16.9% CAGR, the Middle East & Africa Direct-to-Consumer Genetic Testing Market is Projected to be Worth US$ 166.21 million by 2030, Says Business Market Insights

According to Business Market Insights research, the Middle East & Africa direct-to-consumer genetic testing market was valued at US$ 47.58 in 2022 and is expected to reach US$ 166.21 million by 2030, registering a CAGR of 16.9% from 2022 to 2030. Growing incidence of genetic disorders and increasing awareness about potential benefits of genetic testing are among the critical factors attributed to the Middle East & Africa direct-to-consumer genetic testing market expansion.

The global burden of genetic diseases is increasing. According to an article published in 2022 by The Guardian, ~5% of the world's population is affected by sickle cell disease, and approximately 300,000 babies are born with sickle cell anemia worldwide every year. The World Health Organization estimates that 10 in 1,000 people are affected. This means 70 to 80 million people worldwide live with one of these diseases. In 2020, the Online Mendelian Inheritance in Man (OMIM) resource listed 6,594 diseases with known molecular genetic defects, comprising 4,225 genes. This number is continuously increasing to approximately 50-60 new genetic diseases annually, as per the Orphanet and OMIM databases. The NIH Undiagnosed Diseases Program and Network and the International Rare Diseases Research Consortium are a few initiatives further accelerating the discovery rate of novel genetic diseases. The incidence of genetic disorders in newborns is also increasing. According to the World Health Organization 2022 report, neural tube defects, Down syndrome, and heart defects are a few common severe congenital disabilities. According to the report titled "Neural tube defects: Different types and a brief overview of the neurulation process and its clinical implications," published in the Journal of Family Medicine and Primary Care in 2021, more than 300,000 cases of Neural tube defects (NTDs) are recorded worldwide each year. These factors are encouraging the introduction of genetic testing for inherited diseases. Therefore, the increasing incidence of genetic disorders worldwide boosts the direct-to-consumer genetic testing market growth.

On the contrary, high cost and privacy concerns associated with direct-to-consumer genetic testing hamper the growth Middle East & Africa direct-to-consumer genetic testing market .

Based on test type, the Middle East & Africa direct-to-consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing segment held 64.5% share of the Middle East & Africa direct-to-consumer genetic testing market in 2022, amassing US$ 30.69 million. It is projected to garner US$ 103.94 million by 2030 to expand at 16.5% CAGR during 2022-2030.

By technology, the Middle East & Africa direct-to-consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held 68.5% share of Middle East & Africa direct-to-consumer genetic testing market in 2022, amassing US$ 32.57 million. It is projected to garner US$ 116.83 million by 2030 to expand at 17.3% CAGR during 2022-2030.

Based on distribution channel, the Middle East & Africa direct-to-consumer genetic testing market is bifurcated into online and offline. The online segment held 65.5% share of Middle East & Africa direct-to-consumer genetic testing market in 2022, amassing US$ 31.17 million. It is projected to garner US$ 110.26 million by 2030 to expand at 17.1% CAGR during 2022-2030.

Based on country, the Middle East & Africa direct-to-consumer genetic testing market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa. Saudi Arabia held 40.1% share of Middle East & Africa direct-to-consumer genetic testing market in 2022, amassing US$ 19.08 million. It is projected to garner US$ 65.67 million by 2030 to expand at 16.7% CAGR during 2022-2030.

Key players operating in the Middle East & Africa direct-to-consumer genetic testing market are Ancestry Genomics Inc, Living DNA Ltd, 23andMe Inc, and Genetic Technologies Ltd, among others.

- In September 2023; 23andMe Holding Co. and the Sickle Cell 101, have joined forces to expand awareness of people's sickle cell carrier status. The collaboration will include DNA testing and access to 23andMe's Health + Ancestry Service for up to 1,000 eligible participants, and 23andMe will be providing monetary support to Sickle Cell 101 to support this effort.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com